Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Bovine, Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG3|
|Purification||Ion-exchange chromatography, Ammonium sulfate precipitation|
|Storage buffer||PBS, pH 7.4, with 1% BSA|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||2-10µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (Paraffin, Frozen) (IHC (P, F))||See 1 publications below|
OCG-3 recognizes gamma-carboxylated residues 21-31 and does not react with heat decarboxylated Osteocalcin.
Reconstitute with 50µl distilled water to give a 2 mg/ml stock solution.
Prior to the formation of calcified bone, non+collagenous proteins form in the extracellular bone matrix. gamma-carboxyglutamic acid residues are formed by vitamin K, vitamin-D regulated calcium binding proteins containing residues of Gla. These residues are essential for the binding of calcium and constitute 1-2% of total bone protein. Osteocalcin itself binds strongly to apatite and calcium. Production of osteocalcin is expressed late in normal bone development and is characteristic of mature osteoblasts. Regular osteocalcin production has been shown to be linked to the p53 tumor suppressor gene. The p53 gene undergoes rearrangement in a high percentage of osteosarcomas, resulting in loss of its expression. The loss of p53 regulation inhibits further osteocalcin production. The absence of end-point differentiation in bone due to p53 rearrangements and lack of osteocalcin production may contribute to the maintenance of the tumorigenic phenotype in osteosarcomas.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
In vitro osteogenic differentiation is affected in Wiedemann-Rautenstrauch-Syndrome (WRS).
33-5700 was used in immunocytochemistry to study the differentiation capacity of Wiedemann-Rautenstrauch (neonatal progeroid) syndrome progenitor cells
|Jäger M,Thorey F,Westhoff B,Wild A,Krauspe R||In vivo (Athens, Greece) (19:831)||2005|
BGLAP; BGP; bone gamma-carboxyglutamate (gla) protein (osteocalcin); bone Gla protein; gamma-carboxyglutamic acid-containing protein; OC; osteocalcin
BGLAP; BGP; BOS_2768; OC; OCN